Edgar Filing: Posard Matthew L. - Form 4

Posard Matthe Form 4	w L.											
May 02, 2018	4 UNITED	STATES	SECUP	ITIES A	ND FY(тнал	JCF (OMMISSION		PPROVAL		
Check this l	box	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										
if no longer subject to Section 16. Form 4 or Form 5	SIAIE	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								Expires: 2005 Estimated average burden hours per response 0.5		
obligations may continu <i>See</i> Instruct 1(b).	ue. Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Res	sponses)											
1. Name and Address of Reporting Person <u>*</u> Posard Matthew L.			2. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS INC [HALO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			3. Date of Earliest Transaction (Month/Day/Year) 05/02/2018					Officer (give title 10% Owner Officer (give title Other (specify below) below)				
	(Street)			adment, Date Original h/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting 				
SAN DIEGO,		(Zin)						Person				
Security ((Instr. 3)	(State) 2. Transaction Da (Month/Day/Year	r) Executio any	med	3.	4. Securit on(A) or Di (D) (Instr. 3, -	ties Ac sposed	quired of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	f, or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of		
Common Stock	05/02/2018			А	10,363 (1)	А	\$0	102,751	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Posard Matthew L. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. 6. Date Exercisable and orNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Ρ

C 1 S

S

Р

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Posard Matthew L. C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121	Х						
Signatures							
/s/ James R. Oehler as attorney-in-fact for Ma Posard	atthew L. 05/02/2018						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) (1) May 2, 2019 or (ii) the date of the Issuer's next annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.